drugset / Trial / NCT05351554
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
NaSingle-groupOpen-labelTreatment
Summary
A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.
Timeline
- Start
- 2022-08-23
- Primary completion
- 2022-11-15
- Completion
- 2022-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Namilumab | Monoclonal antibody | 150 mg | Subcutaneous |